Andersen, et al., “Adverse drug interactions clinically important for the dermatologist”, Arch Dermatol, Apr., 1995, vol. 131, pp. 468-473. |
Babe, et al., “Histamine, Bradykinn, and their Antagonists” in The Pharmacological Basis of Therapeutics (9th edition), The McGraw-Hill Co. Inc., pp. 581-599 (1996). |
Barnett, et al., “Pharmacology of Non-Sedating H1 Antihistamines”, New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991). |
Berge,et al., “Pharmaceutical Salts”, J. of Pharm. Sciences, Jan., 1977, vol. 66, No.1 pp.1-19. |
Berthon, et al., “In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release form human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)”, Biochem. Pharm., 1994, vol. 47, No. 5, pp. 789-794. |
Blaug, et al., “Interaction of dextroamphetamine sulfate with spray-dried lactose”, J. of Pharm. Sciences, Nov., 1972, vol. 61, No. 11, pp. 1770-1775. |
Brandes, et al., “Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates”, J. of the National Cancer Inst., May 18, 1994, vol. 86, No. 10, pp. 770-775. |
Brandes, et al., “Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses”, Cancer Research, Jul. 1, 1992, vol. 52, pp. 3796-3800. |
Brion, et al., “Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers”, Br. J. Clin. Pharmac. 1988, vol. 25, pp. 27-32. |
Carmeliet, “Voltage-and Time-Dependent Block of the Delayed K+ Current in Cardiac Myocytes by Dofetilide”, The J. of Pharm. And Experimental Therapeutics, 1992, vol. 262, No. 2, pp. 809-817. |
Castello, et al., “Discoloration of tablets containing amines and lactose”, J. of Pharm. Sciences, Feb., 1962, vol. 51, No.2, pp. 106-108. |
Cheung, et al., “Investigation of anti-motion sickness drugs in the squirrel monkey”, J. Clin. Pharmacol, 1992, vol. No. 32, pp. 163-175. |
Clissold, et al., “Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy”, Drugs, 1989,vol. 37, pp. 42-57. |
Cooke, “Glycopyrrolate in bladder dysfunction”, SA Medical Journal, Jan. 1, 1983, p. 3. |
Craft, “Torsade de pointes after astemizole overdose”, Br. Medical Journal, 1986,, vol. 292, p. 660. |
Dorje, et al., “Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes”, The J. of Pharm. And Experimental Therapeutics, 1991, vol. 256, pp. 727-733. |
Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832. |
Ebert, “Soft elastic gelatin capsules: a unique dosage form”, Pharmaceutical Technology, 1977, pp. 44-50. |
Gengo, “Dilemma: Antihistamine selection: Use vs. Side effects”, U.S., Pharmacist, Nov. 1990, pp. 59-92. |
Hartauer, et al., A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction, “Drug Development and industrial Pharmacy”, 1991, vol. 17, No. 4, pp. 617-630. |
Herron, et al, “Dose Proportionality, Linearity, and Pharmacokiinetics of Desloratadine in Healthy Volunteers” (Abstract 1126), J. Allergy Clin. Immunol., Jan., 2000, vol. 105, No. 1, Part 2, p. S385. |
Herzog, et al., “Urinary Incontinence: medical and Psychosocial Aspects”, Annual Review of Gerontology and Geriatrics, 1989, vol. 9, pp. 74-119. |
Hilbert, et al., “Pharmacokinetics and Dose Proportionality of Loratadine”, J. Clin. Pharmacol. 1987, vol. 27, pp. 694-98. |
Housley, et al., “Histamine and related substances influence neurotransmission in the semicircular canal”, Hearing Research, May 1, 1988, vol. 35, pp. 87-97. |
Jankowski, et al., “Effect of Terfenadine on Nnasal Provocation”, Int. Arch. Allergy Immunolog., 1993, vol. 101, pp. 311-317. |
Kaliner, “Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects”, American Family Physician, Mar. 1992, vol. 45, No. 3, pp. 1337-1342. |
Kleine-Tebbe, et al., “Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine”, J. Allergy Clin. Immunol., 1994, vol. 93, pp. 494-500. |
Knowles, “Astemizole and Terfenadine-Induced Cardiovascular Effects”, The Canadian J. of Hospital Pharmacy, Feb., 1992, vol. 45, No. 1, pp. 33 & 37. |
Kohl, et al., “Lack of Effects of Astemizole on Vestibular Ocular Reflex, Motion Sickness, and Cognitive Performance in Man”, Aviation, Space, and Environmental Medicine, Dec., 1987, pp. 1171-1174. |
Kohl, et al., “New Pharmacologic Approaches to the Prevention of Space/Motion Sickness”, J. Clin. Pharmacol., 1991, vol. 31, pp. 934-946. |
Kohl, et al., “Control of Nausea and autonomic dysfunction with terfenadine, a peripherally acting antihistamine”, Aviation, Space and Environmental Medicine, May, 1991, pp. 392-396. |
Kreutner, et al, “Profile of Desloratadine as a Selective and Non-Sedating Histamine H1-Receptor Antagonist”, Preclinical Efficacy and Antiallergic, J. Allergy Clin. Immunol. (Abstract 1118), vol. 105, No. 1, part 2, pp. S382-383. |
Kubo, et al., “Antimuscarine Effects of Antihistamines: Quantitative Evaluation by Receptor-Binding Assay”, Japan J. Pharmacol., 1987, vol. 43, pp. 277-282. |
Lathers, et al., “Pharmacology in space: Part 2. Controlling motion sickness”, TiPS, Jun., 1989, vol. 10, pp. 243-250. |
Levin, et al., “Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder”, The J. of Urology, Aug., 1982, vol. 128, pp. 396-398. |
Lunde, “Antihistamines”, Side Effects of Drugs Annual 14, Elsevier Science Publishers B.V., 1990, pp. 135-138. |
Lunde, “Antihistamines”, Side Effects of Drugs Annual 12: A Worldwide Yearly Survey of New Data and Trends, Elsevier Science Publishers B.V., 1998, pp. 142-143. |
Massad, et al., “The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride”, The J. of Urology, Aug., 1992, vol. 148, pp. 595-597. |
McCue, “Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients”, Arch. Fam. Med., Sep., 1996, vol. 5, pp. 464-468. |
Miadonna, et al., “Inhibitory Effect of the H1 Antagonist Loratadine on Histamine Release from Human Basophils”, Int. Arch. Allergy Immunol., 1994, vol. 105, pp. 12-17. |
Mirakhur, et al., “Glycopyrrolate: Pharmacology and Clinical Use”, Anaesthesia, 1983, vol. 38, pp. 1195-1203. |
Mitchelson, “Pharmacological Agents Affecting Emesis: A Review (Part II)”, Drugs, 1992, vol. 43, No. 4, pp. 443-463. |
Muskat, et al., “The Use of Scopolamine in the Treatment of Detrusor Instability”, The J. of Urology, 1996, vol. 156, pp. 1989-1990. |
Nelemans,“Antiallergic and antitussive drugs”, Side Effects of Drugs Annual 12, Elsevier Science Publishers B.V., 1988, pp. 144-147. |
Nomeir, et al., “Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from the Extended-Release Tablets in Healthy Volunteers”, J. Clin. Pharm, 1996, vol. 36, No. 10, pp. 923-930. |
Padhi, et al., Multiple-Dose Pharmacokinetics; Safety and Tolerance of Desloratadine in Healthy Volunteers (Abstract 1124), Jan. 2000, J. Allergy Clin. Immunol., Jan. 2000, vol. 105, No. 1, part 2, p. S385. |
Parkinson, et al., “Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 in Rats and Mice”, Biochemical Pharmacology, 1992, vol. 43, No. 10, pp. 2169-2180. |
Peggs, et al., “Antihistamines: The Old and the New”, American Family Physician, Aug., 1995, vol. 52, No. 2, pp. 593-600. |
Petrin, “Bewegungskrankheit und ihre Therapie/ Eine Ubersicht (Motion Sickness and its Treatment)”, Schweiz, Rundschau Med., 1974, (PRAXIS) 63, pp. 79-81. |
Quercia, et al., “Focus on Loratadine: A new second-generation nonsedating H1-receptor antagonist”, Hosp. Formul., Feb. 1993, vol. 28, pp. 137, 138, 141, 142, 144, 149, & 153. |
Remington's Pharmaceutical Sciences. 18th Ed, Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1519-1520. |
Remington's Pharmaceutical Sciences. 18th Ed, Alfonso R. Gennaro, Mack Publishing Company, Easton, PA, 1990, pp. 1527-1529. |
Resnick, “Urinary incontinence”, The Lancet, Jul. 8, 1995, vol. 346, pp. 94-99. |
Roman, et al., “Loratadine-A Review of Recent Finding in Pharmacology Pharmacokinetics, Efficacy, and Safety, with a Look at its Use in Combination with Pseudoephedrine”, Clin. Reviews in Allergy, 1993, vol. 11, pp. 89-110. |
Salmun, et al., Efficacy and Safety of Desloratadine in Seasonal Allergic Rhinitis, Jan., 2000, J. Allergy Clin. Immunol. (Abstract 1123), vol. 105, No. 1, Part 2, pp. S384-385. |
Simons, “H1-Receptor Antagonists Comparative Tolerability and Safety”, Drug Safety, 1994, vol. 10, No. 5, pp. 350-380. |
Sunahara, et al., “Pharmacological interventions for motion sickness: Cardiovascular Effects”, Aviation, Space and Environmental Medicine, Sep., 1987, pp. A270-A276. |
Temple, et al., “Loratadine, an Antihistamine, Blocks Antigen-and Ionophore-Induced Leukotriene Release from Human Lung In Vitro”, Protaglandins, Apr. 1988, 35(4):549-554. |
Van Cauwenberge, “New Data on the Safety of Loratine”, Drug Invest., 1992, vol. 4, No. 4, pp. 283-291. |
Van Peer, et al., “Ketoconazole Inhibits Loratadine Metabolism in Man”, Beerse, Belgium, Abstract 1234, p. 34. |
Wade, et al., Handbook of Pharmaceutical Excipients (2nd edition), American Pharmaceutical Association and Pharma Press, Royal Pharma. Society of G. Britain, 1994, pp. 257&259. |
Wein, “Pharmacology of Incontinence”, Urologic Clinics of North America, Aug., 1995, vol. 22, No. 3, pp. 557-577. |
Wirth, et al., Mailland Reaction of Lactose and Fluoxeline Hydrochloride, a Secondary Amine, Journal of Pharmaceutical Sciences, Jan. 1998, vol. 87, No.1, pp.31-39. |
Wood “Antimotion Sickness and Antimetic Drugs”, Drugs, 1979, vol.17, pp. 471-479. |
Wood, et al., “Mechanisms of Antimotion Sickness Drugs”, Aviation, Space, and Environmental Medicine, Sep. 1987, pp. A262-A265. |
The United States Pharmacopeia, The United States Formulary, United States Pharmacopeial Convention, Inc., Rockville, MD. 1989, p. 1990. |
Yarker, et al., “Oxybutynin,. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Use in Detrusor Instability”, Drugs and Aging, 1995, vol. 6, No. 3, pp. 243-262. |
Zhong, et al., “HPLC-Determination of Loratadine and its active metabolite descarboethoxyloratadine in human plasma”, Pharmazie, 1994, vol. 49(H. 10), pp. 736-739. |